The Use of Targeted Cytokines as Cancer Therapeutics in Glioblastoma

Moloud Sooreshjani, Shashwat Tripathi, Corey Dussold, Hinda Najem, John de Groot, Rimas V. Lukas, Amy B. Heimberger*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations

Abstract

Cytokines play an important role in regulating the immune response. Although there is great interest in exploiting cytokines for cancer immunotherapy, their clinical potential is limited by their pleiotropic properties and instability. A variety of cancer cell-intrinsic and extrinsic characteristics pose a barrier to effective treatments including cytokines. Recent studies using gene and cell therapy offer new opportunities for targeting cytokines or their receptors, demonstrating that they are actionable targets. Current efforts such as virotherapy, systemic cytokine therapy, and cellular and gene therapy have provided novel strategies that incorporate cytokines as potential therapeutic strategies for glioblastoma. Ongoing research on characterizing the tumor microenvironment will be informative for prioritization and combinatorial strategies of cytokines for future clinical trials. Unique therapeutic opportunities exist at the convergence of cytokines that play a dual role in tumorigenesis and immune modulation. Here, we discuss the underlying strategies in pre- and clinical trials aiming to enhance treatment outcomes in glioblastoma patients.

Original languageEnglish (US)
Article number3739
JournalCancers
Volume15
Issue number14
DOIs
StatePublished - Jul 2023

Funding

Support was provided by the Lurie Cancer Center and NIH grants P30CA060553, P50CA221747, NS120547, R01CA272639, and CA120813. A.B.H. serves on the advisory board of Caris Life Sciences and WCG Oncology Advisory Board, receives royalty and milestone payments from DNAtrix, and has been supported by research grants from Alnylam, Celularity, and AbbVie. Other material support has been provided by Moleculin, Carthera, and Takeda. A.B.H. has received consulting fees from BlueRock Therapeutics, NovoCure. The rest of the authors declare no conflict of interest.

Keywords

  • cytokines
  • glioma
  • tumor microenvironment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'The Use of Targeted Cytokines as Cancer Therapeutics in Glioblastoma'. Together they form a unique fingerprint.

Cite this